Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
Bosn J Basic Med Sci ; 19(3): 282-287, 2019 Aug 20.
Artículo en Inglés | MEDLINE | ID: mdl-30821220

RESUMEN

Thymic stromal lymphopoietin (TSLP) is a cytokine produced by epithelial cells in the lungs, skin, and intestinal mucosa and is involved in several physiological and pathological processes. In this study, we evaluated serum TSLP levels in patients with celiac disease (CD). The prospective study was conducted at a gastroenterology outpatient clinic between March 2018 and August 2018. Eighty-nine participants aged between 18 and 75 years were classified into following groups: 22 patients with newly diagnosed CD; 20 patients with CD who were compliant with a gluten-free diet (GFD); 32 patients with CD who were not compliant with a GFD; and 15 healthy controls. Demographic characteristics, disease duration, and selected biochemical and hematologic parameters were recorded and compared between groups. Median serum TSLP levels were 1193.65 pg/mL (range: 480.1-1547.1) in newly diagnosed CD patients, 110.25 pg/mL (range: 60.3-216.7) in CD patients who were compliant with a GFD, 113.1 pg/mL (range: 76.3-303.4) in CD patients who were not compliant with a GFD, and 57 pg/mL (range: 49-67.8) in healthy controls. Overall, there was a significant difference in serum TSLP levels between groups (p = 0.001). Patients with newly diagnosed CD had the highest serum TSLP levels. There was no significant difference in serum TSLP levels between patients with CD who were and were not compliant with a GFD. TSLP appears to be involved in the pathogenesis of CD. Further studies are required to determine if the TSLP signaling pathway can be used in the treatment of CD.


Asunto(s)
Enfermedad Celíaca/metabolismo , Citocinas/metabolismo , Adolescente , Adulto , Anciano , Enfermedad Celíaca/dietoterapia , Dieta Sin Gluten , Femenino , Humanos , Masculino , Persona de Mediana Edad , Cooperación del Paciente , Estudios Prospectivos , Adulto Joven
3.
Med Princ Pract ; 28(3): 236-241, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30726852

RESUMEN

OBJECTIVE: Recent studies have demonstrated that angiogenesis is impaired in patients with celiac disease (CD). In this study, we evaluated the levels of the novel antiangiogenic factor pigment epithelium-derived factor (PEDF) in CD patients. METHODS: Eighty-four patients were included in the study; 71 patients with CD and 13 healthy controls. In the CD patient cohort, there were 21 newly diagnosed patients, 19 with adherence to a gluten-free diet and 31 practicing no adherence to this diet. The PEDF levels were measured using enzyme-linked immunosorbent assays. RESULTS: The data revealed that celiac patients had higher levels of PEDF than did healthy controls. PEDF levels were not significantly different among the three CD groups. Additionally, the PEDF levels were not correlated with tissue transglutaminase IgA or IgG. CONCLUSIONS: Our data indicate that PEDF levels are significantly higher in CD patients than those in the healthy controls. This result suggests that PEDF negatively affects angiogenesis in CD. Although we did not observe any differences of PEDF levels among celiac patients, additional studies including more patients could clarify this issue.


Asunto(s)
Enfermedad Celíaca/sangre , Proteínas del Ojo/sangre , Factores de Crecimiento Nervioso/sangre , Serpinas/sangre , Adulto , Enfermedad Celíaca/dietoterapia , Estudios Transversales , Dieta Sin Gluten , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos
4.
Med Princ Pract ; 26(6): 523-529, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29131124

RESUMEN

OBJECTIVE: The aim of this study was to compare the efficacy and safety of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth-containing quadruple therapy as a first-line regimen for the eradication of Helicobacter pylori. METHODS: A total of 329 patients with H. pylori infection were randomly divided into 3 groups to receive one of the following regimens: (a) levofloxacin-containing bismuth quadruple therapy, RBAL (rabeprazole 20 mg, b.i.d., bismuth subsalicylate 562 mg, b.i.d., amoxicillin 1 g, b.i.d, levofloxacin 500 mg, once daily), (b) standard bismuth quadruple therapy, RBMT (rabeprazole 20 mg, b.i.d, subsalicylate 562 mg, b.i.d., metronidazole 500 mg, t.i.d, tetracycline 500 mg, q.i.d), or (c) levofloxacin-containing triple therapy, RAL (rabeprazole 20 mg, b.i.d., amoxicillin 1 g, b.i.d, levofloxacin 500 mg, once daily). The primary outcome was the eradication rate in the intention-to-treat (ITT) and per protocol (PP) analysis. RESULTS: The eradication rates of the above 3 groups using ITT analysis were RBAL 83.8%, RBMT 88.3%, and RAL 74.8% compared with 91.2, 92.5, and 79.2%, respectively, using PP analysis. The eradication rate using RBMT was significantly higher than that of RAL (p = 0.029 in ITT analysis and p = 0.017 in PP analysis). Several side effects occurred in 156 patients (54.1%) in the RBAL group, 215 (52.3%) in the RBMT group, and 56 (26.2%) in the RAL group (p > 0.05, RBAL vs. RBMT; p < 0.001, RBMT vs. RAL; p < 0.001, RBAL vs. RAL). CONCLUSION: All bismuth-containing quadruple therapies had acceptable eradication rates, but levofloxacin-containing triple therapy was not as good as quadruple therapies. Hence, quadruple therapies should be considered the preferred first-line therapy for H. pylori infections.


Asunto(s)
Antibacterianos/uso terapéutico , Bismuto/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Levofloxacino/uso terapéutico , Compuestos Organometálicos/uso terapéutico , Salicilatos/uso terapéutico , Adolescente , Adulto , Anciano , Amoxicilina/uso terapéutico , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Bismuto/administración & dosificación , Bismuto/efectos adversos , Esquema de Medicación , Quimioterapia Combinada , Femenino , Humanos , Levofloxacino/administración & dosificación , Levofloxacino/efectos adversos , Masculino , Metronidazol/uso terapéutico , Persona de Mediana Edad , Compuestos Organometálicos/administración & dosificación , Compuestos Organometálicos/efectos adversos , Salicilatos/administración & dosificación , Salicilatos/efectos adversos , Tetraciclina/uso terapéutico , Adulto Joven
5.
Turk J Med Sci ; 46(5): 1428-1433, 2016 Nov 17.
Artículo en Inglés | MEDLINE | ID: mdl-27966309

RESUMEN

BACKGROUND/AIM: The incidence of acute cholecystitis (AC) increases with age, and aging is also one of the poor prognostic factors. Aging is related to altered physiology, so diseases may show different characteristics in elderly patients. We aimed to investigate the differences between the main characteristic features of AC in elderly and nonelderly patients. MATERIALS AND METHODS: In this retrospective study, patients who had a diagnosis of AC were included and divided into two groups of people aged <65 years or >65 years. Laboratory and ultrasonographic findings related to AC were compared statistically between elderly and nonelderly patients. RESULTS: The data of 305 patients diagnosed with AC were recorded. Patients in the nonelderly group were more likely to be female, but in elderly patients the sex distribution was similar. There were no significant differences with respect to liver function tests and ultrasonographic findings at the time of admission between the elderly and nonelderly groups. However, the elderly group had a significantly higher rate of patients with an elevated white blood cell count and higher C-reactive protein values than the nonelderly group. CONCLUSION: Aging is related to altered immunologic and pathophysiologic processes. Thus, age and baseline comorbidities influence overall mortality rates. Efforts should be made to understand disease mechanisms and minimize avoidable harms.


Asunto(s)
Colecistitis Aguda , Anciano , Femenino , Humanos , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...